Immunological diagnostic of scleroderma;Diagnostic immunologique des sclérodermies

Pathologie Biologie

Volumn 50, Issue 4, 2002, Pages 243-255

  Fabien, Nicole ^a   Rousset, Hugues ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Antinuclear auto antibodies; Diagnosis; Sclerodermia

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; FIBRILLARIN ANTIBODY; NOR 90 ANTIBODY; NUCLEOPHOSMIN ANTIBODY; PM SCL ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RNA POLYMERASE ANTIBODY; SCL 70 ANTIBODY; TO TH ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; HUMAN; MYOSITIS; PATHOGENESIS; PREVALENCE; REVIEW; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

EID: 0036272760     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0369-8114(02)00296-1     Document Type: Review

References (113)

1. Pathology of progressive systemic sclerosis (generalized scleroderma) with special reference to change in the viscera
2. Scleroderma (systemic sclerosis) classification, subsets and pathogenesis
3. Severe organ involvment in systemic sclerosis with diffuse scleroderma
4. Scleroderma and related conditions
5. Facteurs environnementaux et facteurs iatrogènes dans les Sclérodermies systémiques et syndromes associés
6. Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis
7. Immunological aspects of scleroderma
8. Hypertension pulmonaire dans les selérodermies systémiques: Une étude sur 67 patients
9. Atteinte pulmonaire au cours de la selérodermie systémique. Partie I. Pneumopathie interstitielle chronique fibrosante
10. Manifestations cardiovasculaires dans les sclérodermies systémiques
11. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
12. Anti-endothelial cell antibodies in systemic sclerosis
13. Anti-endothelial cell antibodies in systemic sclerosis: Significant association with vascular involvement and alveolocapillary impairment
14. Assessment of anti-endothelial cell antibodies in systemic sclerosis and Sjogren's syndrome
15. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma
16. Autoantibody to centromere (kinetochore) in scleroderma sera
17. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid Arthritis
18. Clinical association of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients
19. Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/sclerodema overlap syndromes
20. Cutaneous and serologic subsets of systemic sclerosis
21. Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma
22. Test performance in systemic sclerosis: Anti-centromère anti Scl-70 antibodies
23. Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis
24. Du syndrome de Thibierge-Weissenbach (1910) aux anticorps anti-centromères (1980)
25. Auto-anticorps anti-Scl-70 et anti-centromères: Marqueurs biologiques de deux formes de Sclérodermie Systémique
26. Autoantibody reactive with RNA polymerase III in systemic sclerosis
27. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis
28. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis
29. Anti-RNA polymerase antibodies in systemic sclerosis (SSc): Association with anti-topoisomerase I antibodies and identification of autoreactive subsets of RNA polymerase II
30. Clinicial correlation and prognosis based on serum autoantibodies in patients with systemic sclerosis (scleroderma)
31. Autoantibodies to topoisomerase I are found in sera from scleroderma patients
32. Scl-70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as topoisomerase 1
33. Topoisomerase 1 identified by scleroderma 70 antisera: Enrichment of topoisomerase 1 at the centromere in mouse mitotic cells before anaphase
34. Human autoantibody to topoisomerase II
35. cDNA cloning, of human topoisomerase I: Catalytic activity of a 67.7 kDa carboxyl-terminal fragment
36. The IgG, IgM and IgA isotypes of antitopoisomerase I and anticentromere autoantibodies
37. Analysis of an immunodominant epitope of Topoisomerase 1 in patients with systemic sclerosis
38. Specificity of anti-ScL-70 antibodies in scleroderma: Increased sensitivity of detection using purified DNA topoisomerase I from calf thymus
39. A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis
40. Antibodies against distinct nuclear matrix proteins are characteristic for mixed connective tissue disease
41. Antinuclear antibodies: Diagnostic makers for autoimmune diseases and probes for cell biology
42. Autoantibodies to topoisomerase I (Scl-70): Analysis by gel diffusion, immunoblot and enzyme-linked immunosorbent assay
43. Preliminary criteria for the classification of Sjögren's syndrome
44. Detection of anti-DNA topoisomerase I antibody by an enzyme-linked immunosorbent assay using overlapping recombinant polypeptides
45. Anti Scl-70 antibodies detected by immunoblotting in progressive systemic sclerosis: Specificity and clinical correlation
46. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma
47. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase antibody
48. Influence de l'âge sur les caractéristiques cliniques et biologiques de la sclérodermie systémique
49. A long-term longitudinal isotypic study of anti topoisomerase I autoantibodies
50. Longitudinal study of anticentromere and antitopoisomerase-I isotypes
51. Scl-86 a marker antigen for diffuse scleroderma
52. Association of anti-topoisomerase I with cancer
53. Sclérodermie systémique et cancers: 21 cas et revue de la littérature
54. Sclérodermie systémique et cancer. Recherche de marqueurs prédictifs des cancers chez 123 patients atteints de Sclérodermie
55. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis
56. International conference on systemic sclerosis: Pathogenesis, clinical features and treatment
57. Three human chromosomal autoantigens are recognized by sera from patients with anti-centromere antibodies
58. The heterogeneity of anticentromere antibodies in immunoblotting analysis
59. Centromere and kinetochore structure
60. Molecular cloning of a major CENP-B epitope and its use for the detection of anticentromere autoantibodies
61. Anticentrornere autoantibodies: Evaluation of an ELISA using-recombinant fusion protein CENP-B as antigen
62. Detection of anticentromere antibodies using recombinant human CENP-A protein
63. Diversity of antinuclear antibodies in progressive systemic sclerosis: Anti-centromere antibody and its relationship to CREST syndrome
64. Anticorps anti-centromère: Valeur diagnostique et pronostique
65. Anti-centromere antibody: Clinical correlations and association with favorable pronosis in patients with scleroderma variants
66. L'anticorps anticentromère, marqueur biologique de la variété CREST de la sclérodermie
67. Immunogenetic associations of scleroderma-related antinuclear antibodies
68. Anticentromere antibodies in subjects with no apparent connective tissue disease
69. Patients with anticentromere antibodies, clinical features, diagnoses and evolution
70. Clinical correlation of anticentromere antibodies
71. Les anticorps anticentromère en pratique rhumatologique ne sont pas toujours associés à une sclérodermie
72. Measurement of functional status, self assessement, and psychological well-being in scleroderma
73. Autoantibodies to mitochondrial and centromere antigens in primary biliary cirrhosis and systemic sclerosis
74. Clinical and immunological characterization of patients with systemic sclerosis overlapping primary biliary cirrhosis: A comparison with patients with systemic sclerosis alone
75. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis
76. Prognostic significance of anticentromere antibodies and antitopoisomerase I antibodies in Raynaud's disease. A prospective study
77. Antinucleolar antibodies
78. Systemic sclerosis (scleroderma) and mixed connective tissue discase
79. Demographic differences in the frequencies of scleroderma-related autoantibodies
80. Racial differences in the frequencies of scleroderma-related autoantibodies
81. Identification of autoantibodies to RNA polvmerase II: Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III
82. Auto-antibody to RNA polymerase I in scleroderma sera
83. Antibodies to distinct polypeptides of RNA polymerase I in sera from patients with rheumatic autoimmune disease
84. Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome: Specific recognition of the phosphorylated (IIO) form by a subset of human sera
85. Analysis of autoantibodies against RNA polymerases using immunoaffinity-purified RNA polymerase I, II and III antigen in an enzyme-linked immunosorbent assay
86. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis
87. Autoantibodies in scleroderma
88. cDNA cloning and sequencing of human fibrillarin: A conserved nucleolar protein recognized by autoimmune sera
89. Analysis of the autoantibody response to fibrillarin in human disease and murine models of auto-immunity
90. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis
91. Autoantibodies to ribonucleoprotein particles by immunoblotting
92. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies
93. Autoantibodies to fibrallarin in systemic sclerosis (scleroderma)
94. Clinical Association of autoantibodies to fibrillarin with diffuse scleroderma and disseminated telangiectasia
95. Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes
96. Analysis of the specificity of anti-PM-Scl auto-antibodies
97. Nucleolar localisation of the PM-Scl antigen
98. Detection and quantification of human anti-PM-Scl autoantibodies using recombinant PM-Scl protein
99. Antinuclear and antinucleolar antibodies in patients with sclerodermapolymyositis overlap syndrome
100. Serum autoantibody to the nucleolar antigen PM-Scl: Clinical and immunogenetic associations
101. Human autoantibody to RNA polvmerase I transcription factor huBF: Molecular identity of nucleolus organizer region autoantigen NOR-90 and ribosomal RNA transcription upstream binding factor
102. Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera: Two MR forms of NOR90/hUBF autoantigens
103. Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis
104. HLA clinical associations in systemic sclerosis patients with anti-Th/To antibodies
105. Human autoantibodies against a nucleolar protein
106. Autoantibodies to the extracellular matrix microfibrillar protein, Fibrillin-1, in patients with scleroderma and other connective tissue diseases
107. The relationship between serum immunogobulin levels and pulmonary involvement in systemic sclerosis
108. Antibodies to snRNPs in systemic lupus erythematosus
109. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis
110. Distribution and antigen specificity of anfi-U1RNP antibodies in patients with systemic sclerosis
111. Muscle disease in progressive systemic sclerosis: Diagnostic and therapeutic considerations
112. Frequency levels and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis
113. Autoantibodies in the diagnosis of systemic rheumatic diseases